Immunization of Immunosuppressed Patients
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".
Deadline for manuscript submissions: 31 July 2025 | Viewed by 212
Special Issue Editors
Interests: coagulation; convalescent plasma therapy
Special Issues, Collections and Topics in MDPI journals
Interests: virology; hematology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Mass vaccination campaigns have largely mitigated the healthcare burden of COVID-19, and booster vaccinations are being regularly updated. Nevertheless, vaccine response and efficacy remain suboptimal, mainly in those who need care the most, i.e., immunocompromised patients. In this Special Issue, we will analyze the effectiveness of different COVID-19 vaccine formulations across different cohorts of immunocompromised patients. Cohorts will range from oncohematological patients to solid organ transplant recipients to patients with autoimmune disorders. The Special Issue welcomes original research studies on novel vaccine approaches (e.g., mucosal delivery or novel adjuvants) and epidemiological studies or rigorous systematic reviews on vaccine efficacy in particular cohorts of immunocompromised patients.
We look forward to receiving your contributions.
Dr. Massimo Franchini
Dr. Daniele Focosi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- COVID-19
- vaccine efficacy
- immunization
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
